Citadel Advisors
AYTU icon

Citadel Advisors’s AYTU BioPharma AYTU Stock Holding History

Citadel Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Buy
36,841
+21,290
+137% +$54.4K ﹤0.01% 12019
2025
Q4 		$40.4K Buy
+15,551
New +$34.9K ﹤0.01% 12132
2025
Q2 		– Sell
-30,493
Closed -$36.6K – 12518
2025
Q1 		$36.6K Buy
30,493
+19,431
+176% +$28.3K ﹤0.01% 12620
2024
Q4 		$18.5K Buy
+11,062
New +$20.2K ﹤0.01% 13229
2024
Q3 		– Sell
-21,810
Closed -$63.5K – 14223
2024
Q2 		$63.5K Buy
21,810
+9,635
+79% +$29.1K ﹤0.01% 11499
2024
Q1 		$37K Buy
+12,175
New +$34.8K ﹤0.01% 12476
2022
Q1 		– Sell
-4,906
Closed -$122K – 13553
2021
Q4 		$132K Buy
4,906
+528
+12% +$22.8K ﹤0.01% 12424
2021
Q3 		$252K Buy
4,378
+3,159
+259% +$237K ﹤0.01% 11462
2021
Q2 		$122K Sell
1,219
-19
-2% -$2.23K ﹤0.01% 12728
2021
Q1 		$188K Sell
1,238
-2,946
-70% -$468K ﹤0.01% 11776
2020
Q4 		$500K Buy
4,184
+4,128
+7,371% +$752K ﹤0.01% 8143
2020
Q3 		$13K Buy
+56
New +$14.4K ﹤0.01% 9918
2020
Q2 		– Sell
-208
Closed -$62K – 9753
2020
Q1 		$62K Buy
+208
New +$40.2K ﹤0.01% 8922
2019
Q4 		– Sell
-64
Closed -$15K – 9092
2019
Q3 		$15K Buy
+64
New +$19.3K ﹤0.01% 8998
2019
Q1 		– Sell
-141
Closed -$22K – 9241
2018
Q4 		$22K Buy
+141
New +$31.1K ﹤0.01% 8703
2018
Q3 		– Sell
-77
Closed -$81K – 9189
2018
Q2 		$81K Buy
77
+55
+250% +$91.8K ﹤0.01% 8319
2018
Q1 		$56K Buy
+22
New +$151K ﹤0.01% 7898

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's AYTU Position: Q1 2026 in Review

Citadel Advisors increased its AYTU BioPharma (AYTU) stake by 137% in Q1 2026, buying an estimated $54.4K and bringing the position to 36,841 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #12019.

Citadel Advisors first reported a position in AYTU in Q1 2018 and has held it in 17 quarters since. The position peaked at $500K in Q4 2020. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

  • Citadel Advisors held 36,841 shares of AYTU BioPharma worth $101K as of Q1 2026.
  • Citadel Advisors bought 21,290 AYTU BioPharma shares in Q1 2026, an estimated $54.4K.
  • AYTU BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12019 holding.
  • Citadel Advisors first reported a position in AYTU BioPharma in Q1 2018 and has held it in 17 quarters since.
  • Citadel Advisors's AYTU BioPharma position peaked at $500K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.